???global.info.a_carregar???
Nuno André Carvalho da Fonseca. Completed the Mestrado integrado in Mestrado Integrado em Ciências Farmacêuticas in 2009/07 by Universidade de Coimbra Faculdade de Farmácia and Doutoramento in Doutoramento em Ciências Farmacêuticas, especialidade de Tecnologia Farmacêutica in 2015/07 by Universidade de Coimbra Faculdade de Farmácia. Is Research Assistant in Universidade de Coimbra Centro de Neurociências e Biologia Celular. Published 16 articles in journals. Has 5 section(s) of books. Has 1 patent(s) registered. Participated in 8 event(s). Co-supervised 1 MSc dissertation(s). Has received 4 awards and/or honors. Participates and/or participated as PhD Student Fellow in 1 project(s), Post-doc in 1 project(s) and Researcher in 1 project(s). Works in the area(s) of Medical and Health Sciences with emphasis on Health Sciences, Engineering and Technology with emphasis on Nano-technology, Medical and Health Sciences with emphasis on Medical Biotechnology with emphasis on Health-Related Biotechnology, Natural sciences with emphasis on Biological Sciences with emphasis on Cell Biology and Medical and Health Sciences with emphasis on Medical Biotechnology with emphasis on Technologies Involving the Manipulation of Cells, Tissues, Organs or the Whole Organism. In their professional activities interacted with 144 collaborator(s) co-authorship of scientific papers. In his curriculum Ciência Vitae the most frequent terms in the context of scientific, technological and artistic-cultural output are: combinatorial ratiometric drug design; triple negative breast cancer; C6-ceramide; nanoparticles; F3-targeted delivery; cancer stem cells; non-stem cancer cells; nanotechnology; breast cancer; drug combinations; tumor recurrence; siRNA delivery; Lipid-based nanosystems; DNA nanocarriers; nucleolin; systemic drug delivery; targeting cancer stem cells; cancer; mesothelioma; Liposome Technology; doxorubicin; targeted nanoparticles; heterotypic microenvironment; cancer modeling; metastasis; tissue engineering; mesenchymal stem cells; nanofiber; antibacterial; lung cancer; anti-angiogenic resistance; gene delivery; cancer biology; tumor microenvironment; angiogenesis; proliferation; cell division; molecular targets; drug resistance; metabolic pathways; cytotoxic ligands; cancer therapy; targeting; CAR-T; CAR-T cell; chimeric antigen receptor; tumor targeting; Immunotherapy; immunoresistance; microarray; .
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Nuno André Carvalho da Fonseca

Nomes de citação

  • Fonseca, Nuno A.

Identificadores de autor

Ciência ID
C01F-8090-3B04
ORCID iD
0000-0003-4970-7288
Google Scholar ID
https://scholar.google.pt/citations?user=AQdApQkAAAAJ&hl=pt-PT
Researcher Id
AAF-1747-2020
Scopus Author Id
https://www.scopus.com/authid/detail.uri?authorId=56343290600

Endereços de correio eletrónico

  • nuno.fonseca@cnc.uc.pt (Profissional)

Telefones

Telefone
  • 239820190 (Profissional)

Moradas

  • Rua Larga, Faculdade de Medicina, Pólo 1, 1º Andar, 3004-504, Coimbra, Coimbra, Portugal (Profissional)

Websites

Domínios de atuação

  • Ciências Médicas e da Saúde - Ciências da Saúde
  • Ciências da Engenharia e Tecnologias - Nanotecnologia
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Biotecnologia Aplicada à Saúde
  • Ciências Naturais - Ciências Biológicas - Biologia Celular
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Tecnologias que envolvem a Manipulação de Células,Tecidos,Órgãos ou todo o Organismo

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Português (Idioma materno)
Inglês Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Francês Utilizador elementar (A1) Utilizador elementar (A2) Utilizador elementar (A1) Utilizador elementar (A1) Utilizador elementar (A1)
Formação
Grau Classificação
2010/02 - 2015/07
Concluído
 Doutoramento em Ciências Farmacêuticas, especialidade de Tecnologia Farmacêutica (Doutoramento)
Universidade de Coimbra Faculdade de Farmácia, Portugal
"Targeted intracellular delivery of synergistic drug combinations: tackling drug resistance in human breast cancer." (TESE/DISSERTAÇÃO)
 Aprovado com distinção e louvor
2004/09 - 2009/07
Concluído
 Mestrado Integrado em Ciências Farmacêuticas (Mestrado integrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
 16
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2020/07/01 - 2021/03/31 Assistente de Investigação (carreira) (Investigação) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2019/02/01 - 2020/06/30 Pós-doutorado (Investigação) Universidade de Coimbra, Portugal
Centre for Innovative Biomedicine and Biotechnology, Portugal
2016/11/01 - 2019/01/31 Pós-doutorado (Investigação) CNC.IBILI, Portugal
CNC.IBILI, Portugal
2010/02/01 - 2014/01/31 Investigador (Investigação) CNC.IBILI, Portugal

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2021/04/01 - Atual Formulation Scientist Bluepharma, Portugal
2014/02 - 2016/10 Associate Director of Research & Development TREAT U, SA, Portugal
Projetos

Bolsa

Designação Financiadores
2016 - 2019 Towards a single therapy with a synergistic drug combination against triple negative breast cancer and neuroblastoma by nucleolin-mediated multicellular targeting
NanoDoxer
Investigador Pós-doutorado
Fundação para Ciência e Tecnologia
Em curso
2010/02 - 2014/01 Targeted intracellular delivery of synergistic drug combinations: tackling drug resistance in human breast cancer
SFRH/BD/64243/2009
Bolseiro de Doutoramento
Fundação para Ciência Tecnologia
2012 - 2013 ANTI-STEM CELLS - Targeted delivery of drug combinations towards cancer stem cells
ANTI-STEM CELLS
Investigador
CNC.IBILI, Portugal
 InovC - Universidade de Coimbra
Concluído
Produções

Publicações

Artigo em conferência
  1. Chiara, Brignole; Bensa, Veronica; Zotto, Genny Del; Bruno, Silvia; Fonseca, Nuno A; Cruz, Ana F; Paolo, Daniela Di; et al. "Abstract A101: Nucleolin: A novel cell surface protein for neuroblastoma targeted therapy". Boston, 2019.
    Publicado • 10.1158/1535-7163.targ-19-a101
  2. Fonseca, Nuno A.; Moura, Vera; Colelli, Fabiana; Pesce, Daniela; Signorino, Giacomo; Focareta, Laura; Fucci, Alessandra; et al. "Abstract 2994: In vivo targeting of mesothelioma’s molecular signature with nanoparticle functionalized with nucleolin-binding peptide". Trabalho apresentado em Annual Meeting of the American Association for Cancer Research 2019, 2019.
    Publicado • 10.1158/1538-7445.am2019-2994
  3. Cruz, Ana F.; Fonseca, Nuno A.; Gonçalves, Nélio; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "Abstract 3622: Differential effect of liposomal C6-ceramide/doxorubicin targeted to nucleolin and conventional combinations against triple negative breast cancer stem cells". Trabalho apresentado em Annual Meeting of the American Association for Cancer Research 2019, 2019.
    Publicado • 10.1158/1538-7445.am2019-3622
  4. Ana Filipa Cruz; Nuno André Fonseca; Susana F. Sampaio; Vera Moura; Ramiro D. Almeida; Sérgio Simões; João Nuno Moreira. "Abstract 2194: Synergistic cytotoxicity of targeted liposomes containing doxorubicin and C6-ceramide against nucleolin-overexpressing ovarian cancer cells is supported by the downregulation of the Akt pathway". Trabalho apresentado em American Association for Cancer Research Annual Meeting 2017, 2017.
    Publicado • 10.1158/1538-7445.am2017-2194
  5. Nuno André Fonseca; Vera Moura; Fabiana Colelli; Daniela Pesce; Francesco Cardile; Claudio Pisano; Sérgio Simões; João Nuno Moreira. "Abstract 5155: Targeting nucleolin with doxorubicin-containing nanoparticle induces a significant tumor growth inhibition in an orthotopic animal model of standard of care-resistant mesothelioma". Trabalho apresentado em American Association for Cancer Research Annual Meeting 2017, 2017.
    Publicado • 10.1158/1538-7445.am2017-5155
  6. A. Valério-Fernandes; N. Fonseca; V. Moura; A. Ladeirinha; T. Ferreira; A. Alarcão; L. Carvalho; S. Simões; J.N. Moreira. "600: Targeting nucleolin in lung cancer - an emerging strategy to overcome stroma-mediated anti-VEGF resistance". Trabalho apresentado em 23rd Biennial Congress of the European Association for Cancer Research, 2014.
    Publicado • 10.1016/s0959-8049(14)50533-3
  7. A. Gregório; N. Fonseca; V. Moura; G. Domingues; M. Lacerda; P. Figueireido; S. Simões; S. Dias; J.N. Moreira. "749: Targeting cell-surface nucleolin in metastatic breast cancer". Trabalho apresentado em 23rd Biennial Congress of the European Association for Cancer Research, 2014.
    Publicado • 10.1016/s0959-8049(14)50657-0
  8. Ângela Valério-Fernandes; Nuno Fonseca; Vera Moura; Ana Ladeirinha; Teresa Ferreira; Ana Alarcão; Lina Carvalho; Sérgio Simões; João Nuno Moreira. "Abstract 3003: Targeting nucleolin: A potential strategy to overcome stroma-mediated bevacizumab resistance in lung cancer". Trabalho apresentado em 105th Annual Meeting of the American Association for Cancer Research, 2014.
    Publicado • 10.1158/1538-7445.am2014-3003
  9. Monteiro, Nelson; Martins, Albino; Pires, Ricardo; Faria, Susana; Fonseca, Nuno A; Moreira, João N.; Reis, Rui L.; Neves, Nuno M.. "TS40 - Immobilization of bioactive factor-loaded liposomes at the surface of electrospun nanofibers targeting tissue engineering strategies". Trabalho apresentado em TERM STEM 2013 Nanotechnology as a Tool for Improving Tissue Engineering and Regenerative Medicine, 2013.
    Publicado • 10.1002/term.1822
Artigo em revista
  1. Fonseca, Nuno A.; Gregório, Ana C.; Mendes, Vera M.; Lopes, Rui; Abreu, Teresa; Gonçalves, Nélio; Manadas, Bruno; et al. "GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure". Nano Today 37 (2021): 101095. http://dx.doi.org/10.1016/j.nantod.2021.101095 IMPACT FACTOR (2019 JCR): 16.907.
    Publicado • 10.1016/j.nantod.2021.101095
  2. Carvalho, Laura Sofia; Gonçalves, Nélio; Fonseca, Nuno André; Moreira, João Nuno. "Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis". Pharmaceuticals 14 1 (2021): 60. http://dx.doi.org/10.3390/ph14010060. IMPACT FACTOR (JCR 2019): 4.286.
    Publicado • 10.3390/ph14010060
  3. Abreu, Teresa R.; Fonseca, Nuno A.; Gonçalves, Nélio; Moreira, João Nuno. "Current challenges and emerging opportunities of CAR-T cell therapies". Journal of Controlled Release 319 (2020): 246-261. http://dx.doi.org/10.1016/j.jconrel.2019.12.047. Impact Factor (2018 JCR): 7.727.
    Publicado • 10.1016/j.jconrel.2019.12.047
  4. Romano, Sofia; Fonseca, Nuno; Simões, Sérgio; Gonçalves, João; Moreira, João Nuno. "Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands". Drug Discovery Today 24 10 (2019): 1985-2001. http://dx.doi.org/10.1016/j.drudis.2019.06.018. IMPACT FACTOR (2019 JCR): 7.321.
    Publicado • 10.1016/j.drudis.2019.06.018
  5. Cruz, Ana Filipa; Fonseca, Nuno Andre; Moura, Vera; Simoes, Sergio; Moreira, Joao Nuno. "Targeting Cancer Stem Cells and Non-Stem Cancer Cells: The Potential of Lipid- Based Nanoparticles". Current Pharmaceutical Design 23 43 (2018): 6563-6572. http://dx.doi.org/10.2174/1381612823666171115105252. Impact Factor (2019 JCR): 2.208.
    Publicado • 10.2174/1381612823666171115105252
  6. Fonseca, Nuno A.; Cruz, Ana Filipa; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors". Critical Reviews in Oncology/Hematology 113 (2017): 111-121. http://dx.doi.org/10.1016/j.critrevonc.2017.03.016. Impact Factor (2019 JCR): 5.833.
    Publicado • 10.1016/j.critrevonc.2017.03.016
  7. Gregório, Ana C.; Fonseca, Nuno A.; Moura, Vera; Lacerda, Manuela; Figueiredo, Paulo; Simões, Sérgio; Dias, Sérgio; Moreira, João Nuno. "Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model". PLOS ONE 11 11 (2016): e0165817. http://dx.doi.org/10.1371/journal.pone.0165817. Impact Factor (2019 JCR): 2.740.
    Publicado • 10.1371/journal.pone.0165817
  8. Monteiro, Nelson; Martins, Albino; Pires, Ricardo A.; Faria, Susana; Fonseca, Nuno A.; Moreira, João N.; Reis, Rui L.; Neves, Nuno M.. "Dual release of a hydrophilic and a hydrophobic osteogenic factor from a single liposome". RSC Advances 6 115 (2016): 114599-114612. http://dx.doi.org/10.1039/c6ra21623d. Impact Factor (2019 JCR): 3.119.
    Publicado • 10.1039/c6ra21623d
  9. Fonseca, Nuno A.; Rodrigues, Ana S.; Rodrigues-Santos, Paulo; Alves, Vera; Gregório, Ana C.; Valério-Fernandes, Ângela; Gomes-da-Silva, Lígia C.; et al. "Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination". Biomaterials 69 (2015): 76-88. http://dx.doi.org/10.1016/j.biomaterials.2015.08.007. Impact Factor (2019 JCR): 10.317.
    Publicado • 10.1016/j.biomaterials.2015.08.007
  10. Monteiro, Nelson; Martins, Albino; Ribeiro, Diana; Faria, Susana; Fonseca, Nuno A.; Moreira, João N.; Reis, Rui L.; Neves, Nuno M.. "On the use of dexamethasone-loaded liposomes to induce the osteogenic differentiation of human mesenchymal stem cells". Journal of Tissue Engineering and Regenerative Medicine 9 9 (2015): 1056-1066. http://dx.doi.org/10.1002/term.1817. Impact Factor (2019 JCR): 3.078.
    Publicado • 10.1002/term.1817
  11. Monteiro, Nelson; Martins, Margarida; Martins, Albino; Fonseca, Nuno A.; Moreira, João N.; Reis, Rui L.; Neves, Nuno M.. "Antibacterial activity of chitosan nanofiber meshes with liposomes immobilized releasing gentamicin". Acta Biomaterialia 18 (2015): 196-205. http://dx.doi.org/10.1016/j.actbio.2015.02.018. Impact Factor (2019 JCR): 7.242.
    Publicado • 10.1016/j.actbio.2015.02.018
  12. Fonseca, Nuno A.; Gomes-da-Silva, Lígia C.; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination". Journal of Controlled Release 196 (2014): 122-131. http://dx.doi.org/10.1016/j.jconrel.2014.09.024. Impact Factor (2019 JCR): 7.727.
    10.1016/j.jconrel.2014.09.024
  13. Monteiro, Nelson; Ribeiro, Diana; Martins, Albino; Faria, Susana; Fonseca, Nuno A.; Moreira, João N.; Reis, Rui L.; Neves, Nuno M.. "Instructive Nanofibrous Scaffold Comprising Runt-Related Transcription Factor 2 Gene Delivery for Bone Tissue Engineering". ACS Nano 8 8 (2014): 8082-8094. http://dx.doi.org/10.1021/nn5021049. Impact Factor (2019 JCR): 14.588.
    Publicado • 10.1021/nn5021049
  14. Fonseca, Nuno A.; Gregório, Ana C.; Valério-Fernandes, Ângela; Simões, Sérgio; Moreira, João N.. "Bridging cancer biology and the patients' needs with nanotechnology-based approaches". Cancer Treatment Reviews 40 5 (2014): 626-635. http://dx.doi.org/10.1016/j.ctrv.2014.02.002. Impact Factor (2019 JCR): 8.885.
    Publicado • 10.1016/j.ctrv.2014.02.002
  15. Monteiro, Nelson; Martins, Albino; Pires, Ricardo; Faria, Susana; Fonseca, Nuno A.; Moreira, João N.; Reis, Rui L.; Neves, Nuno M.. "Immobilization of bioactive factor-loaded liposomes on the surface of electrospun nanofibers targeting tissue engineering". Biomater. Sci. 2 9 (2014): 1195-1209. http://dx.doi.org/10.1039/c4bm00069b. Impact Factor (2019 JCR): 6.183.
    Publicado • 10.1039/c4bm00069b
  16. Gomes-da-Silva, Lígia C.; Fonseca, Nuno A.; Moura, Vera; Pedroso de Lima, Maria C.; Simões, Sérgio; Moreira, João N.. "Lipid-Based Nanoparticles for siRNA Delivery in Cancer Therapy: Paradigms and Challenges". Accounts of Chemical Research 45 7 (2012): 1163-1171. http://dx.doi.org/10.1021/ar300048p. Impact Factor (2019 JCR): 20.834.
    10.1021/ar300048p
Capítulo de livro
  1. Abreu, Teresa R.; Biscaia, Mariana; Gonçalves, Nélio; Fonseca, Nuno A.; Moreira, João Nuno. "In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles". In Advances in Experimental Medicine and Biology, 271-299. Springer International Publishing, 2021.
    10.1007/978-3-030-58174-9_12
  2. Cruz, Ana Filipa; Fonseca, Nuno A.; Gregório, Ana C.; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "Moving Liposome Technology from the Bench to the Oncological Patient: Towards Performance-by-Design". In Particles and Nanoparticles in Pharmaceutical Products, 171-211. Springer International Publishing, 2018.
    10.1007/978-3-319-94174-5_4
  3. Fonseca, Nuno A.; Lopes, Rui M.; Cruz, Ana F.; Gregório, Ana C.; Valério-Fernandes, Ângela; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "Lipid-Based Nanosystems for the Delivery of siRNA: Challenges and Trends". In Handbook of Nanomaterials for Cancer Theranostics, 495-515. Elsevier, 2018.
    10.1016/b978-0-12-813339-2.00016-5
  4. Lopes, R.M.; Fonseca, N.A.; Cruz, A.F.; Gregório, A.C.; Valério-Fernandes, Â.; Moura, V.; Simões, S.; Moreira, J.N.. "Advances on nucleic acid delivery with nonviral vectors". In Bioinspired Materials for Medical Applications, 403-426. Elsevier, 2017.
    10.1016/b978-0-08-100741-9.00014-0
  5. Moura, V.; da Silva, L.C.G.; Fonseca, N.A.; de Lima, M.C.P.; Simões, S.; Moreira, J.N.. "Emerging targets and novel nanotechnology-based strategies: Changing the treatment paradigm in oncology". 2011.
Poster em conferência
  1. Carvalho, Laura Sofia; Pechincha, Catarina; Gonçalves, Nélio; Cruz, A.F.; Ramalho, José S; Fonseca, Nuno A.; Moreira, João N.. "Nucleolin downregulation in triple negative breast cancer cells: a key protein for phenotypic aggressiveness?". Trabalho apresentado em BEBday 2019, 2019.
  2. Carvalho, Laura Sofia; Pechincha, Catarina; Gonçalves, Nélio; Fonseca, Nuno A.; Cruz, Ana F.; Ramalho, José S; Moreira, Joao N. "Nucleolin downregulation in triple negative breast cancer cells: exploring the phenotypic implications of a therapeutic target". Trabalho apresentado em 1st Annual Meeting in Pharmaceutical Sciences., 2019.
  3. Cruz, A.F.; Fonseca, Nuno A.; Gonçalves, Nélio; Moura, V; Simões, Sérgio; Moreira, Joao N. "Synergistic cytotoxicity of targeted liposomal C6-ceramide and doxorubicin against nucleolin-overexpressing cancer cells is supported by the downregulation of the PI3K/Akt pathway". Trabalho apresentado em 1st Annual Meeting in Pharmaceutical Sciences, 2019.
  4. Abreu, T; Lopes, Rui; Fonseca, Nuno A.; Moreira, Joao N. "Specific recognition of the onco-target nucleolin by the tumor homing F3 peptide". Trabalho apresentado em 1st Annual Meeting in Pharmaceutical Sciences, 2019.
  5. Biscaia-Caleiras, Mariana; Fonseca, Nuno A.; Cruz, A.F.; Gonçalves, Nélio; Moreira, João N.. "Targeted delivery of doxorubicin and C6-ceramide combinations to non-small cell lung cancer cells - Key factors for C6-ceramide's cytotoxocity". Trabalho apresentado em 1st Annual Meeting in Pharmaceutical Sciences, 2019.
  6. Cruz, A.F.; Fonseca, Nuno A.; Gonçalves, Nélio; Moura, V; Simões, Sérgio; Moreira, João N.. "The Potential Of Liposomal C6-ceramide/doxorubicin Targeted To Nucleolin To Decrease Triple-negative Breast Cancer Stem Cell Population, Relative To A Standard Of Treatment". Trabalho apresentado em 2019 Controlled Release Society Annual Meeting; 2019 July 20-24; Valencia, Spain, 2019, 2019.
  7. Fonseca, Nuno A.; Moura, Vera; Colleli, Fabiana; Daniela Pesce; Giacomo Signorino; Focareta, Laura; Alessandra Fucci; et al. "Nucleolin-mediated Drug Delivery Blocks Growth Of Biphasic Mesothelioma Through Disruption Of Its Molecular Signature". Trabalho apresentado em 2019 Controlled Release Society Annual Meeting; 2019 July 20-24; Valencia, Spain, 2019, 2019.
  8. Fonseca, Nuno; Gregório, A. C; Mendes, V.; Lopes, R.; Manadas, B.; Lacerda, M.; Figueiredo, P.; et al. "Tumor intracellular bioavailability of doxorubicin determines therapeutic efficacy of nanoparticle targeted to nucleolin.". Trabalho apresentado em 3rd ASPIC INTERNATIONAL CONGRESS, 2018.
  9. Valério-Fernandes, Ângela; Fonseca, Nuno; Moura, V.; Ladeirinha, A.; Ferreira, T.; Alarcão, A.; Carvalho, L.; Simões, S.; Moreira, J. N.. "Nucleolin in lung cancer – an emerging target to overcome stroma-mediated anti-angiogenic resistance.". Trabalho apresentado em 1ST ASPIC INTERNATIONAL CONGRESS, 2014, 2014.
  10. Fonseca, Nuno A.; Rodrigues, A.S.; Rodrigues-Santos, P.; Alves, V.; Rosa, M.S.; Moura, V.; Ramalho-Santos, J.; Simões, S.; Moreira, J. N.. "Nucleolin-­mediated targeting of breast cancer cell sub­populations with different stem-like phenotype.". Trabalho apresentado em 1ST ASPIC INTERNATIONAL CONGRESS, 2014, 2014.
  11. Gregório, A. C; Fonseca, Nuno A.; Moura, V.; Domingues, G.; Lacerda, M.; Figueiredo, P.; Simões, S.; Dias, S.; Moreira, J. N.. "Targeting cell surface nucleolin in metastatic breast cancer.". Trabalho apresentado em 1ST ASPIC INTERNATIONAL CONGRESS, 2014., 2014.
  12. Valério-Fernandes, Â.; Fonseca, Nuno A.; Moura, V.; Ladeirinha, A.; Ferreira, T.; Alarcão, A.; Carvalho, L.; Simões, S.; Moreira, J. N.. "Nucleolin-mediating targeting of the tumor microenvironment in bevacizumab-resistant Lung Cancer". Trabalho apresentado em Xth Spanish-Portuguese Conference on Controlled Drug Delivery: Drug Delivery Systems from Lab to Clinic – New Trends and Opportunities, 2013.
  13. Valério-Fernandes, Â.; Fonseca, Nuno A.; Moura, V.; Ladeirinha, A.; Ferreira, T.; Alarcão, A.; Carvalho, L.; Simões, S.; Moreira, J. N.. "Nucleolin-mediating targeting of the tumor microenvironment in bevacizumab-resistant Lung Cancer". Trabalho apresentado em EMBO YOUNG SCIENTISTS’ FORUM 15–16 July 2013, 2013.
  14. Fonseca, Nuno A.; Simões, S.; Moreira, J. N.. "Rational design of synergistic drug combinations against breast cancer". Trabalho apresentado em EMBO YOUNG SCIENTISTS’ FORUM 15–16 July 2013, 2013.
  15. Monteiro, N.; Martins, A.; Ribeiro, D.; Faria, S.; Fonseca, Nuno A.; Moreira, J. N.; Reis, R.L.; Neves, N.M.. "On the Use of Dexamethasone Loaded Liposomes to Induce the Osteogenic Differentiation of Human Mesenchymal Stem Cells.". Trabalho apresentado em 2013 ANNUAL MEETING OF THE SOCIETY FOR BIOMATERIALS (SFB),, 2013.
  16. Monteiro, N.; Martins, A.; Pires, R.; Faria, S.; Fonseca, Nuno A.; Moreira, J. N.; Reis, R.L.; Neves, N.M.. "Release of Bioactive Agent from Liposomes Immobilized on Electrospun Nanofibers Targeting Tissue Engineering Applications". Trabalho apresentado em 2013 ANNUAL MEETING OF THE SOCIETY FOR BIOMATERIALS (SFB), 2013.
  17. Valério-Fernandes, Â.; Fonseca, Nuno A.; Ladeirinha, A.; Ferreira, T.; Alarcão, A.; Carvalho, L.; Simões, S.; Moreira, J. N.. "Assessing the potential of nucleolin-targeted stratafies against Lung Cancer resistant to anti-VEGF therapies.". Trabalho apresentado em XXII PORTO CANCER MEETING & III PORTO-BORDEAUX JOINT MEETING - TRANSLATIONAL RESEARCH IN CANCER - BRINGING BASIC SCIENCE AND PATHOLOGY TO CLINICAL ONCOLOGY, 2013.
Resumo em conferência
  1. Fonseca, Nuno A.; Rodrigues, A.S.; Rodrigues-Santos, P.; Alves, V.; Rosa, M.S.; Moura, V.; Ramalho-Santos, J.; Simões, S.; Moreira, J. N.. "Targeting cancer stem cells… and beyond?!". Trabalho apresentado em XI CNC ANNUAL MEETING - BRINGING RESEARCHERS TOGETHER, Cantanhedes, 2014.
Tese / Dissertação
  1. Fonseca, Nuno André Carvalho da. "Targeted intracellular delivery of synergistic drug combinations: tackling drug resistance in human breast cancer". Doutoramento, 2015. http://hdl.handle.net/10316/27016.

Propriedade Intelectual

Patente
  1. Fonseca, Nuno; Gomes-da-Silva, Lígia C; Moura, Vera; Simões, Sérgio; Moreira, Joao N. 2018. "Platform for targeted delivery to stem cells and tumor cells and methods thereof. EP2983720B1".
    Concedida/Emitida
Pedido provisório de patente
  1. 2018. "Nucleolin-mediated intracellular drug release inhibits tumor growth at low systemic exposure. PCT/PT2019/050034".
    Protegido
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2019/07 Nucleolin-mediated Drug Delivery Blocks Growth Of Biphasic Mesothelioma Through Disruption Of Its Molecular Signature 2019 Controlled Release Society Annual Meeting; 2019 July 20-24
Controlled Release Society (Valencia, Espanha)
2018/10 Cancer “Diálogos com Cientistas - Desafios na Saúde: Doenças do Séc. XXI”
IEC – Instituto de Educação e Cidadania. (Aveiro, Portugal)
2018/07 Targeting solid tumors with lipid-based nanoparticles 2018 Seminar Series, BEB -PhD Programme
CNC.IBILI (Coimbra, Portugal)
2018/01/16 Tumor intracellular bioavailability of doxorubicin determines therapeutic efficacy of GLP grade nanoparticle targeted to nucleolin independently of systemic exposure. XII Spanish-Portuguese Conference on Controlled Drug Delivery
Spanish-Portuguese Local Chapter of the Controlled Release Society (Coimbra, Portugal)
2017/05 Addressing the tumor microenvironment with targeted nanotechnologies Evaluation Event of Everis Awards 2017
Everis Foundation (Madrid, Espanha)

Orientação

Título / Tema
Papel desempenhado 		Curso (Tipo)
Instituição / Organização
2018/09 - Atual Tumor delivery of synergistic drug combinations
Coorientador
 Pharmaceutical Biotechnology Masters (Mestrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2014 - 2014 Adobe Illustrator for Sciences.
Oficina (workshop)
CNC.IBILI, Portugal
2014 - 2014 How to write a competitive proposal for HORIZON 2020.
Oficina (workshop)
Associação para a Inovação e Desenvolvimento em Ciência e Tecnologia, Portugal
2014 - 2014 Animal experimentation certification - Category B
Outro
 Laboratory animals course.
CNC.IBILI, Portugal
2014 - 2014 EACR-23: From Basic Research to Personalized Cancer Treatment. Munich, Germany
Congresso
European Association For Cancer Research, Reino Unido
2012 - 2012 LabLinks: Tumor Microenvironment. United Kingdom.
Simpósio
King's College London, Reino Unido
2012 - 2012 Workshop on Microarray Applications in Biomedicine
Oficina (workshop)
Biocant Associação de Transferência de Tecnologia, Portugal
2011 - 2011 Champalimaud Cancer Research Symposium in tribute to the work of Judah Folkman
Simpósio
Fundação Champalimaud, Portugal
2010 - 2010 Survival or death as a matter of fat.
Congresso
CNC.IBILI, Portugal

Comissão de avaliação

Descrição da atividade
Tipo de assessoria 		Instituição / Organização Entidade financiadora
2017 - 2018 Participation in MSs and Post-Doc fellowship evaluation panels under the project "HealthyAging2020" - CENTRO-01-0145-FEDER-000012
Membro
 Universidade de Coimbra, Portugal Comissão de Coordenação e Desenvolvimento Regional do Centro
2016 - 2017 Participation in MSc or Post-Doc fellowship evaluation panels under the project "ODD4PEGASEMP - PEGASEMP™ as an orphan drug for the treatment of rare diseases: a curative therapy for mesothelioma" - CENTRO-01-0247-FEDER-017646 (funded by the European Fund for Regional Development (FEDER), through the Regional Operational Program for the Center Region of Portugal (Centro 2020))
Membro
 Universidade de Coimbra, Portugal Comissão de Coordenação e Desenvolvimento Regional do Centro

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2020/12/05 - 2020/12/05 TARGETED DELIVERY OF SYNERGISTIC DRUG COMBINATIONS: Tackling cancer stem cells in human breast cancer Masters in Pharmaceutical Biotechnology (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2019/05 - 2019/05 Nucleolin-targeted delivery: from enhanced tumor accumulation to cancer stem cell targeting (Doutoramento) CNC.IBILI, Portugal
2019 - 2019 TARGETED DELIVERY OF SYNERGISTIC DRUG COMBINATIONS: Tackling cancer stem cells in human breast cancer Pharmaceutical Biotechnology Masters 2019-2020 (Mestrado) (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2018 - 2018 Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. Pharmaceutical Biotechnology Masters 2018-2019 (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2018 - 2018 Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. Principles and Practice in Drug Development MIT-PORTUGAL Program 2017/2018, (Doutoramento) CNC.IBILI, Portugal
2017 - 2017 Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. Pharmaceutical Biotechnology Masters 2017/2018 (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2017 - 2017 Tackling breast cancer stem cells through targeted delivery of synergistic combinations. Principles and Practice in Drug Development MIT-PORTUGAL Program 2016-2017 (Doutoramento) CNC.IBILI, Portugal
2016 - 2016 Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. Pharmaceutical Biotechnology Masters 2016/2017 (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2016 - 2016 Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. Principles and Practice in Drug Development MIT-PORTUGAL Program 2015/2016 (Doutoramento) CNC.IBILI, Portugal
2016 - 2016 Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. Advanced Therapeutics 2016, BEB PhD Program (Doutoramento) CNC.IBILI, Portugal
2015 - 2015 Targeted intracellular delivery of synergistic combinations: tackling drug resistance in human breast cancer. Principles and Practice in Drug Development MIT-PORTUGAL Program 2014/2015 (Doutoramento) CNC.IBILI, Portugal
2014 - 2014 Nanotechnology mediated targeting of cancer stem cells. Pharmaceutical Biotechnology Masters 2014/2015 (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2012 - 2012 FACS as a tool for drug delivery, gene silencing and cell viability assessment. CNC Cores – BEB PhD Programme, (Doutoramento) CNC.IBILI, Portugal
2011 - 2011 Drug Delivery, Gene Silencing and Viability Impact Assessment by Flow Cytometry CNC Cores – BEB PhD Programme (Doutoramento) CNC.IBILI, Portugal

Tutoria

Tópico Nome do aluno
2017/06 - 2018/01 ODD4PEGASEMP - PEGASEMP™ as an orphan drug for the treatment of rare diseases: a curative therapy for mesothelioma (CENTRO-01-0247-FEDER-017646) Sónia Pinho
2017/01 - 2018/01 ODD4PEGASEMP - PEGASEMP™ as an orphan drug for the treatment of rare diseases: a curative therapy for mesothelioma (CENTRO-01-0247-FEDER-017646) Ana Rafaela Oliveira
2017/09 - 2017/09 Module 8 - Minimally invasive procedures without anaesthesia in mouse and rats (administration of substances) n/a
2012 - 2016 Meeting the needs of breast cancer: a nucleolin's perspective Gregório, Ana Cristina Leal
2012 - 2016 Targeting Nucleolin in Lung Cancer: Towards a Personalized Therapy Fernandes, Ângela Filipa Valério
2014 - 2015 Impacto de uma nova estratégia nanoterapêutica em células estaminais tumorais de cancro do pulmão Araújo, Rute Silva
2013 - 2014 Caracterização físico-química e biológica da nanopartículas para o tratamento de leucemias Cecílio, Susana Cristina Cristo
2012 - 2013 Desenvolvimento de nanopartículas para o tratamento do cancro Monteiro, Vanessa Filipa Florêncio
Distinções

Prémio

2013 The poster entitled "Assessing the potential of nucleolin-targeted strategies against Lung Cancer resistant to anti-VEGF therapies" won Best Poster Presentation in the category of Translational & Clinical Research

Outra distinção

2018 FDA granted the orphan designation for PEGASEMP™(doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31 aminoacid peptide targeting nucleolin).
US Food and Drug Administration, Estados Unidos
2017 European Commission granted TREAT U, S.A., Portugal, the orphan designation for doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin for the treatment of malignant mesothelioma.
European Medicines Agency, Reino Unido
2014 Scale-up under GMP of a targeted liposomal formulation.
TREAT U, SA, Portugal